Dr. Farley R. Cleghorn is senior vice president and chief technical officer of Futures Group. Dr. Cleghorn has more than 20 years of experience in international development, research, and program implementation. His research has focused on the epidemiology, natural history, prevention, and pathogenesis of HIV/AIDS and related infections in the United States and the developing world. He has made many original contributions to the field of human retrovirology in the areas of HIV-1 and HTLV-I epidemiology, natural history, pathogenesis, prevention, and treatment.

Dr. Cleghorn is a leading international expert on HIV/AIDS and the development of research and programs in developing countries to reduce HIV transmission and the impact of AIDS. In 2004, he left the University of Maryland Medical Center to join Futures Group to help broaden its HIV/AIDS portfolio and develop a set of core activities in service delivery and infectious diseases under the U.S. President’s Emergency Plan for AIDS Relief. From 1995 to 2004, Dr. Cleghorn served at the University of Maryland as assistant professor of medicine and epidemiology, deputy director of the Division of Epidemiology and Prevention, and senior scientist in the university’s Institute of Virology directed by Dr. Robert Gallo. During his tenure, he built a division and research program of recognized excellence. He is an expert on HIV/AIDS, combination prevention approaches, incidence estimation surveillance and epidemiology, clinical vaccine trials, studies of HIV molecular subtypes and progression to AIDS, antiretroviral treatment, and capacity building training.

Dr. Cleghorn earned an MD (with honors) at the University of the West Indies Faculty of Medical Sciences in 1982 and received an MPH (Alpha Delta Omega) in epidemiology and biostatistics of infectious diseases from Johns Hopkins University School of Hygiene and Public Health in 1992. He is trained in internal medicine and infectious diseases and he completed a fellowship in HIV/AIDS at the National Cancer Institute of the U.S. National Institutes of Health in 1992.

He is the recipient of numerous awards for outstanding scientific and leadership contributions in the field of HIV/AIDS, including the Charles C. Shepard award from the Centers for Disease Control and Prevention in 1998 and for vaccine research and innovative and creative contributions from the HIV Vaccine Trials Network in 2004.